These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37277843)

  • 1. Early acute cerebellar ataxia after meningococcal B vaccine: a case report of a 7-month-old infant and a review of the literature.
    Monzani NA; Corsello A; Tagliabue C; Pinzani R; Mauri E; Agostoni C; Milani GP; Dilena R
    Ital J Pediatr; 2023 Jun; 49(1):61. PubMed ID: 37277843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute cerebellar ataxia following meningococcal group C conjugate vaccination.
    Cutroneo PM; Italiano D; Trifirò G; Tortorella G; Russo A; Isola S; Caputi AP; Spina E
    J Child Neurol; 2014 Jan; 29(1):128-30. PubMed ID: 23275434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute cerebellar ataxia in the Netherlands: a study on the association with vaccinations and varicella zoster infection.
    van der Maas NA; Bondt PE; de Melker H; Kemmeren JM
    Vaccine; 2009 Mar; 27(13):1970-3. PubMed ID: 19186201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of meningococcal serogroup B disease in children after implementation of routine infant 4CMenB vaccination in England: an active, prospective, national surveillance study.
    Mensah AA; Campbell H; Clark SA; Ribeiro S; Lucidarme J; Bai X; Borrow R; Ladhani SN
    Lancet Child Adolesc Health; 2023 Mar; 7(3):190-198. PubMed ID: 36736341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
    Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
    Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme--New challenges for public health.
    Ladhani SN; Campbell H; Parikh SR; Saliba V; Borrow R; Ramsay M
    J Infect; 2015 Dec; 71(6):611-4. PubMed ID: 26433141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study.
    Parikh SR; Andrews NJ; Beebeejaun K; Campbell H; Ribeiro S; Ward C; White JM; Borrow R; Ramsay ME; Ladhani SN
    Lancet; 2016 Dec; 388(10061):2775-2782. PubMed ID: 28100432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute cerebellar ataxia after immunisation with recombinant hepatitis B vaccine.
    Deisenhammer F; Pohl P; Bösch S; Schmidauer C
    Acta Neurol Scand; 1994 Jun; 89(6):462-3. PubMed ID: 7976236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute cerebellitis in children: an eleven year retrospective multicentric study in Italy.
    Lancella L; Esposito S; Galli ML; Bozzola E; Labalestra V; Boccuzzi E; Krzysztofiak A; Cursi L; Gattinara GC; Mirante N; Buonsenso D; Tagliabue C; Castellazzi L; Montagnani C; Tersigni C; Valentini P; Capozza M; Pata D; Di Gangi M; Dones P; Garazzino S; Baroero L; Verrotti A; Melzi ML; Sacco M; Germano M; Greco F; Uga E; Crichiutti G; Villani A
    Ital J Pediatr; 2017 Jun; 43(1):54. PubMed ID: 28606112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of acute cerebellar ataxia and human papilloma virus vaccination: a case report.
    Yonee C; Toyoshima M; Maegaki Y; Kodama Y; Hayami H; Takahashi Y; Kusunoki S; Uchibori A; Chiba A; Kawano Y
    Neuropediatrics; 2013 Oct; 44(5):265-7. PubMed ID: 23378179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.
    Abdelnour A; Silas PE; Lamas MR; Aragón CF; Chiu NC; Chiu CH; Acuña TH; Castrejón Tde L; Izu A; Odrljin T; Smolenov I; Hohenboken M; Dull PM
    Vaccine; 2014 Feb; 32(8):965-72. PubMed ID: 24397906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute Cerebellitis or Postinfectious Cerebellar Ataxia? Clinical and Imaging Features in Acute Cerebellitis.
    Yildirim M; Gocmen R; Konuskan B; Parlak S; Yalnizoglu D; Anlar B
    J Child Neurol; 2020 May; 35(6):380-388. PubMed ID: 32160830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.
    Burman C; Alderfer J; Snow VT
    J Clin Pharm Ther; 2020 Apr; 45(2):270-281. PubMed ID: 31820483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
    Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
    BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UK parents' attitudes towards meningococcal group B (MenB) vaccination: a qualitative analysis.
    Jackson C; Yarwood J; Saliba V; Bedford H
    BMJ Open; 2017 May; 7(4):e012851. PubMed ID: 28473508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute ataxia in children: Common causes and yield of diagnostic work-up in the era of varicella vaccination.
    Segal E; Schif A; Kasis I; Ravid S
    J Clin Neurosci; 2019 Oct; 68():146-150. PubMed ID: 31327588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of meningococcal vaccination with 4CMenB (Bexsero®) in children with invasive meningococcal group B (MenB) disease in England.
    Ladhani SN; Campbell H; Amin-Chowdhury Z; Lucidarme J; Borrow R; Ramsay ME
    Vaccine; 2022 Mar; 40(10):1493-1498. PubMed ID: 35148913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months.
    Østergaard L; Vesikari T; Senders SD; Flodmark CE; Kosina P; Jiang HQ; Maguire JD; Absalon J; Jansen KU; Harris SL; Maansson R; Balmer P; Beeslaar J; Perez JL
    Vaccine; 2021 Jul; 39(32):4545-4554. PubMed ID: 34215452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.
    Vesikari T; Esposito S; Prymula R; Ypma E; Kohl I; Toneatto D; Dull P; Kimura A;
    Lancet; 2013 Mar; 381(9869):825-35. PubMed ID: 23324563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic resonance imaging of acute cerebellar ataxia: report of a case with gadolinium enhancement and review of the literature.
    Kato Z; Shimozawa N; Kokuzawa J; Iwamura M; Hirata T; Yamagishi A; Hayashi T; Motoyoshi T; Kondo N
    Acta Paediatr Jpn; 1998 Apr; 40(2):138-42. PubMed ID: 9581304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.